Get the Stockscreener App
7.09
3.50%
0.24
4 D Molecular Therapeutics Inc stock is traded at $7.09, with a volume of 446.23K.
It is up +3.50% in the last 24 hours and up +57.56% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$6.85
Open:
$6.91
24h Volume:
446.23K
Relative Volume:
0.43
Market Cap:
$331.12M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.6654
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-2.34%
1M Performance:
+57.56%
6M Performance:
+52.80%
1Y Performance:
-51.00%
1-Day Range:
$6.88
$7.33
1-Week Range:
$6.35
$7.59
52-Week Range:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
7.09 | 339.53M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
What institutional flow reveals about 4D Molecular Therapeutics Inc.2025 Dividend Review & Verified Entry Point Detection - Newser
What indicators show strength in 4D Molecular Therapeutics Inc.July 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
Price momentum metrics for 4D Molecular Therapeutics Inc. explainedMarket Volume Summary & Weekly High Conviction Ideas - Newser
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.Weekly Market Outlook & Weekly High Return Stock Opportunities - Newser
4D Molecular Therapeutics Inc. stock chart pattern explained2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Relief Rally in 4D Molecular Therapeutics Inc. Stock — Can It Hold2025 Market WrapUp & Free Daily Entry Point Trade Alerts - newsyoung.net
Candlestick Signal Suggests Reversal in 4D Molecular Therapeutics Inc.Analyst Downgrade & Weekly Watchlist of Top Performers - 선데이타임즈
Predicting 4D Molecular Therapeutics Inc. trend using moving averagesPortfolio Performance Summary & Growth Focused Investment Plans - Newser
Market reaction to 4D Molecular Therapeutics Inc.’s recent news2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
How to escape a deep drawdown in 4D Molecular Therapeutics Inc.Weekly Earnings Recap & Community Verified Trade Signals - Newser
Volatility clustering patterns for 4D Molecular Therapeutics Inc.2025 Performance Recap & Comprehensive Market Scan Insights - Newser
Is 4D Molecular Therapeutics Inc. meeting your algorithmic filter criteriaTrade Analysis Report & Risk Managed Trade Strategies - Newser
4D Molecular Therapeutics Inc. stock prediction for this weekWeekly Trade Analysis & Reliable Intraday Trade Alerts - Newser
Can trapped investors hope for a rebound in 4D Molecular Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - Newser
Is 4D Molecular Therapeutics Inc. forming a reversal patternJuly 2025 Movers & High Conviction Trade Alerts - Newser
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attention - Newser
Will 4D Molecular Therapeutics Inc. price bounce be sustainableJuly 2025 Levels & Low Risk Entry Point Guides - Newser
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $38.00 at Roth Capital - MarketBeat
4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape - MSN
4D Molecular Therapeutics Advances Clinical Programs in Q2 2025 - TipRanks
58,900 RSUs Awarded: 4D Molecular Therapeutics Strengthens Team with New Employee Inducement Grants - Stock Titan
Chardan Capital Maintains "Buy" Rating for 4D Molecular Therapeutics with $25 Target - AInvest
Advanced analytics toolkit walkthrough for 4D Molecular Therapeutics Inc.Weekly Trade Review & Daily Chart Pattern Signal Reports - Newser
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
What is HC Wainwright’s Estimate for FDMT Q3 Earnings? - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability hurdles - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $38.00 by Analysts at Roth Capital - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Receives “Buy” Rating from Chardan Capital - Defense World
Can you recover from losses in 4D Molecular Therapeutics Inc.Risk Aware Trading Ideas with Alert Levels - Newser
What makes 4D Molecular Therapeutics Inc. stock price move sharplyRisk Aware Trading Ideas with Alert Levels - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityHigh Return Strategy with Low Risk - Newser
4D Molecular: Roth Capital Maintains Buy, PT Down to $38 from $44 - AInvest
Using AI based signals to follow 4D Molecular Therapeutics Inc.Consistent Gain Plan with AI Support - Newser
Chardan Capital Raises PT on 4D Molecular to $25. - AInvest
Published on: 2025-08-12 01:26:37 - Newser
Will earnings trigger a reversal in 4D Molecular Therapeutics Inc.Free Pattern Breakout Entry Stock Forecast - Newser
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
4D Molecular Therapeutics Tightens Belt While Chasing FDA Approval - Finimize
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Spectral Ai, Inc. shares rise 1.64% premarket after 4D Molecular Therapeutics reported positive 60-week results from 4D-150 SPECTRA clinical trial in DME. - AInvest
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4 D Molecular Therapeutics Inc Stock (FDMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer |
Sep 16 '24 |
Sale |
16.33 |
500 |
8,165 |
6,781 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):